Product How it works Pricing Blog FAQ About Contact
4D Molecular Therapeutics

4D Molecular Therapeutics (NASDAQ: FDMT) revenue

4D Molecular Therapeutics reported revenue of $85.2m for fiscal 2025, 230,194.6% more than in fiscal 2024 ($0.0m). Since fiscal 2019 its revenue has grown by 1,119.7%, an average growth of 51.7% a year.

Fiscal 2025 is the highest of the 7 fiscal years on record for 4D Molecular Therapeutics. The biggest drop was in fiscal 2024, −99.8%.

Revenue, in millions of US dollars7.0201913.6202018.020213.1202220.720230.0202485.22025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$85.2m+230,194.6%−$159.5m−187.2%
2024$0.0m−99.8%−$187.8m−507,678.4%
2023$20.7m+562.3%−$112.9m−544.6%
2022$3.1m−82.7%−$110.0m−3,516.5%
2021$18.0m+32.5%−$71.3m−395.5%
2020$13.6m+94.8%−$56.7m−416.3%
2019$7.0m—−$50.8m−726.7%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

4D Molecular Therapeutics revenue compared with its sector

By revenue for its latest fiscal year, 4D Molecular Therapeutics ranks 295th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; 4D Molecular Therapeutics, 230,194.6%.

RankCompanyRevenueRevenue growth
293rdCytokinetics$88.0m376.6%
294thDelcath Systems$85.2m129.1%
295th4D Molecular Therapeutics$85.2m230,194.6%
296thARS Pharmaceuticals$84.3m−5.5%
297thNurix Therapeutics$84.0m54.0%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of 4D Molecular Therapeutics

How much revenue did 4D Molecular Therapeutics make in fiscal 2025?
4D Molecular Therapeutics reported revenue of $85.2m for fiscal 2025, compared with $0.0m in fiscal 2024.
How much has the revenue of 4D Molecular Therapeutics grown?
Between fiscal 2019 and fiscal 2025 it went from $7.0m to $85.2m: 1,119.7% more, an average growth of 51.7% a year.
What was the best year for revenue at 4D Molecular Therapeutics?
Of its last 7 fiscal years, fiscal 2025, with $85.2m.
Where does 4D Molecular Therapeutics rank in its sector by revenue?
It ranks 295th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for 4D Molecular Therapeutics come from?
From the annual report (Form 10-K) that 4D Molecular Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that 4D Molecular Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on 4D Molecular Therapeutics: the 4D Molecular Therapeutics page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.